Clinicopathological Characteristics of Diffuse Large B-Cell Lymphoma Not Otherwise Specified in Dr. Hasan Sadikin General Hospital Bandung from 2018 to 2023

Abstract

Introduction

Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) is the most common group of non-Hodgkin malignant lymphoma globally, representing 25%-40% of adult lymphoma cases. According to the cell of origin (COO), DLBCL NOS is classified into DLBCL germinal center B-cell like (GCB) and DLBCL non-germinal center B-cell like (non-GCB). Since the COO affects the prognosis of DLBCL NOS, this examination is important. Hans algorithm is the most frequently used to distinguish the GCB from non-GCB. This study aims to describe the clinicopathological characteristics of DLBCL NOS at Dr. Hasan Sadikin General Hospital Bandung from 2018 to 2023.

Methods

The subjects of this retrospective descriptive study were DLBCL GCB and non-GCB patients based on Hans algorithm by IHC examination of CD10, BCL6, and MUM1 who received R-CHOP therapy at Dr. Hasan Sadikin General Hospital from 2018 to 2023. All data contained age,gender,B symptoms,primary tumor location, stage, total International Prognostic Index (IPI) score, and immunochemotherapy status.

 Results

A total of 55 patients diagnosed with DLBCL NOS were collected in this study 50 patients(90,9%) were classified as DLBCL non-GCB and 5 patients(9,1%) were classified as DLBCL GCB. The average age was 62 years old, predominantly males(52,7%), extranodal disease(54,5%), no B symptoms(76,4%), early stage(83,7%). 52 patients(94,6%) had total IPI score of 0-1, 3 patients(5,4%) had total IPI score of 2. 21 patients(38,2%) had response, 13 patients(23,6%) had non-response and 21 patients(38,2%) are still ongoing to R-CHOP therapy.

 Conclusion

DLBCL NOS at Dr. Hasan Sadikin General Hospital from 2018-2023 mainly occurred in men with average age of 62 years and extranodal disease without B symptoms. DLBCL non-GCB was predominant than GCB. Both DLBCL Non-GCB and GCB were mostly diagnosed at an early stage, IPI low-risk group and had a response status to R-CHOP therapy similar to those are still ongoing to R-CHOP therapy.